Literature DB >> 9829291

Effect of kava extract and individual kavapyrones on neurotransmitter levels in the nucleus accumbens of rats.

S S Baum1, R Hill, H Rommelspacher.   

Abstract

1. Kavapyrones have well-known psychotropic properties. The most common actions of the extract are relaxation and euphoria, depending on the circumstances of ingestion, whereas higher doses cause sleepiness and skeletal muscle relaxation. Several other actions have been reported such as anticonvulsant properties, neuroprotection and analgesia. No interactions with neuroreceptors have yet been found that would explain the multiple actions. 2. To reveal neuronal functions affected by the kavapyrones the authors studied their actions on the mesolimbic reward system using in vivo microdialysis. 3. A small dose of kava extract (20 mg/kg body weight i.p.) caused changes in rat behaviour and concentrations of dopamine in the nucleus accumbens. Higher doses (120 mg/kg i.p.) increased the levels of dopamine. With respect to the individual compounds, D,L-kawain induced in low doses a decrease in dopamine levels and in higher amounts either an increase or no change in dopamine concentrations. Yangonin resulted in a decrease of dopamine levels to below the detection limit and desmethoxyyangonin in an increase of dopamine levels. Dihydrokawain, methysticin and dihydromethysticin did not produce any significant changes of dopamine levels. D,L-kawain caused a decrease in 5-HT concentrations. Some of the other kavapyrones affected 5-HT levels as well. 4. The results suggest that the relaxing and slightly euphoric actions may be caused by the activation of the mesolimbic dopaminergic neurones. Changes of the activity of 5-HT neurones could explain the sleep-inducing action.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9829291     DOI: 10.1016/s0278-5846(98)00062-1

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  16 in total

1.  Novel psychoactive substances of interest for psychiatry.

Authors:  Fabrizio Schifano; Laura Orsolini; G Duccio Papanti; John M Corkery
Journal:  World Psychiatry       Date:  2015-02       Impact factor: 49.548

Review 2.  Plant-based medicines for anxiety disorders, part 2: a review of clinical studies with supporting preclinical evidence.

Authors:  Jerome Sarris; Erica McIntyre; David A Camfield
Journal:  CNS Drugs       Date:  2013-04       Impact factor: 5.749

Review 3.  Therapeutic potential of kava in the treatment of anxiety disorders.

Authors:  Yadhu N Singh; Nirbhay N Singh
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

4.  A systematic review of the safety of kava extract in the treatment of anxiety.

Authors:  Clare Stevinson; Alyson Huntley; Edzard Ernst
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

5.  Kavalactone content and chemotype of kava beverages prepared from roots and rhizomes of Isa and Mahakea varieties and extraction efficiency of kavalactones using different solvents.

Authors:  Jun Wang; Weiyue Qu; Harry C Bittenbender; Qing X Li
Journal:  J Food Sci Technol       Date:  2013-06-25       Impact factor: 2.701

Review 6.  Herb-drug interactions: a literature review.

Authors:  Zeping Hu; Xiaoxia Yang; Paul Chi Lui Ho; Sui Yung Chan; Paul Wan Sia Heng; Eli Chan; Wei Duan; Hwee Ling Koh; Shufeng Zhou
Journal:  Drugs       Date:  2005       Impact factor: 9.546

7.  Extracts of kava (Piper methysticum) induce acute anxiolytic-like behavioral changes in mice.

Authors:  Kennon M Garrett; Garo Basmadjian; Ikhlas A Khan; Brian T Schaneberg; Thomas W Seale
Journal:  Psychopharmacology (Berl)       Date:  2003-07-04       Impact factor: 4.530

8.  The effect of Piper laetispicum extract (EAE-P) during chronic unpredictable mild stress based on interrelationship of inflammatory cytokines, apoptosis cytokines and neurotrophin in the hippocampus.

Authors:  Hui Xie; Di Jin; Yun Kang; Xueru Shi; Hongrui Liu; Haixing Shen; Jian Chen; Macheng Yan; Juan Liu; ShengLi Pan
Journal:  BMC Complement Altern Med       Date:  2015-07-17       Impact factor: 3.659

9.  A stable isotope dilution tandem mass spectrometry method of major kavalactones and its applications.

Authors:  Yi Wang; Shainnel O Eans; Heather M Stacy; Sreekanth C Narayanapillai; Abhisheak Sharma; Naomi Fujioka; Linda Haddad; Jay McLaughlin; Bonnie A Avery; Chengguo Xing
Journal:  PLoS One       Date:  2018-05-24       Impact factor: 3.240

10.  Kava for the treatment of generalised anxiety disorder (K-GAD): study protocol for a randomised controlled trial.

Authors:  Karen M Savage; Con K Stough; Gerard J Byrne; Andrew Scholey; Chad Bousman; Jenifer Murphy; Patricia Macdonald; Chao Suo; Matthew Hughes; Stuart Thomas; Rolf Teschke; Chengguo Xing; Jerome Sarris
Journal:  Trials       Date:  2015-11-02       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.